Basic Information
| LncRNA/CircRNA Name | BC200 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000236824 |
| Refseq | NR_001568 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR |
| Sample | MCF10A, MCF10F, MCF-7, T-47D, MDA-MB-231, and SK-BR-3, Normal and Cancer breast tissue |
| Expression Pattern | up-regulated |
| Function Description | The poorly studied oncogenic BC200 was selected to be tested in vitro and in vivo to determine its relevance in breast cancer and also to provide us with an understanding of its role in the increased susceptibility of the nulliparous women to cancer. Our results show that BC200 is upregulated in nulliparous women, and breast cancer cells and tissue. The role of BC200 is not completely understood in any of the breast cancer subtypes. We here provide evidence that BC200 has a role in luminal breast cancer as well as in the triple negative breast cancer subtype. When overexpressed in luminal and triple negative breast cancer cell lines, BC200 shows increased proliferation, migration, and invasion in vitro. In vivo, overexpression of BC200 increased tumor size. |
| Pubmed ID | 31646972 |
| Year | 2019 |
| Title | BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis |
External Links
| Links for BC200 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |